Abstract

Most postmarketing studies of dipeptidyl peptidase–4 (DPP-4) inhibitors for treating patients with type 2 diabetes have shown no excess cardiovascular risk; however, one randomized trial reported that heart failure–related hospitalizations were more common with saxagliptin (Onglyza) than with placebo (NEJM JW Gen Med Oct 1 2013 …

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call